Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus

摘要

Apart from lifestyle and dietary modification, oral sulfonylureas and thiazolidinediones can prevent or delay hyperglycemic relapse after the discontinuation of insulin. Potential oral monotherapies that have been studied include low-dose glipizide (0.625-2.5 mg/day); low-dose glyburide (1.25-2.5 mg/day) and pioglitazone (30 mg/day). Overall, C-peptide response to glucagon appears to be the best predictor of remission in ketosis-prone diabetes mellitus.